Analyst Activity – Leerink Swann Initiates Coverage On Adaptimmune Therapeutics (NASDAQ:ADAP) With a Buy

Analyst Ratings For Adaptimmune Therapeutics (NASDAQ:ADAP)

Today, Leerink Swann initiated coverage on Adaptimmune Therapeutics (NASDAQ:ADAP) with a Buy with a price target of $15.00.

Some recent analyst ratings include

  • 3/16/2018-Leerink Swann initiated coverage with a Buy rating.
  • 11/10/2017-SunTrust Banks Reiterated Rating of Buy.
  • 6/6/2017-Cowen Reiterated Rating of Buy.
  • 3/17/2017-Wells Fargo & Co initiated coverage with a Market Perform rating.
  • 10/24/2016-Bank of America was Downgraded by analysts at Bank of America from a “Neutral ” rating to a ” Underperform” rating.
  • 9/30/2016-Raymond James Financial initiated coverage with a Outperform rating.

Recent Insider Trading Activity For Adaptimmune Therapeutics (NASDAQ:ADAP)
Adaptimmune Therapeutics (NASDAQ:ADAP) has insider ownership of 24.45% and institutional ownership of 55.58%.

  • On 3/27/2017 Enterprise Associates 14 New, Major Shareholder, bought 12,870,000 with an average share price of $0.70 per share and the total transaction amounting to $9,009,000.00.
  • On 3/27/2017 Orbimed Advisors Llc, Director, bought 1,190,476 with an average share price of $4.20 per share and the total transaction amounting to $4,999,999.20.
  • On 5/24/2016 Orbimed Advisors Llc, Director, bought 1,712,400 with an average share price of $10.42 per share and the total transaction amounting to $17,843,208.00.
  • On 5/19/2016 Charles Elliott Sigal, Director, bought 15,000 with an average share price of $1.56 per share and the total transaction amounting to $23,400.00.
  • On 5/18/2016 Charles Elliott Sigal, Director, bought 45,000 with an average share price of $1.53 per share and the total transaction amounting to $68,850.00.

Recent Trading Activity for Adaptimmune Therapeutics (NASDAQ:ADAP)
Shares of Adaptimmune Therapeutics closed the previous trading session at with 310343 shares trading hands.

An ad to help with our costs